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Abstract
We describe the case of a 34 year-old man with diagnosis of migraine with and without aura that
developed myopia and acute glaucoma after 7 days of treatment with topiramate. The patient had
also been taking citalopram daily for two months. Both topiramate and citalopram have been
related to the increase of intraocular pressure and the development of glaucoma. We can't exclude
that in this patient citalopram caused an increase of the ocular pressure in dose-dependent manner,
facilitating topiramate-induced glaucoma. We recommend to pay particular attention in prescribing
of topiramate in migraine patients who are already under treatment with citalopram or other
antidepressants with a similar mechanisms of action.
Introduction
Topiramate is approved as first or second choice in antie-
pileptic therapy, as an additional therapy for the syn-
drome of Lennox-Gastaut, and for the prophylaxis of
migraine with or without aura in adult patients that have
not responded or are intolerant to the other standard ther-
apies [1]. Topiramate has also been prescribed for a vari-
ety of "off-label" conditions, such as affective disorders,
postherpetic neuralgias, peripheral neuropathies, post-
traumatic stress disorder, loss of weight, and insomnia
[2].
The most common adverse events related to topiramate
are represented by fatigue, paresthesia, alterations of taste,
loss of weight, and drowsiness. In patients treated with
topiramate, a rare but severe adverse event is represented
by acute myopia with secondary closed-angle glaucoma.
In the reported cases of glaucoma, the dose of topiramate
varied from 50 mgs or less (47% of cases), to 50–75 mg
(33% of cases), and 100 mg (13%) to more than 100 mg
(7%) and this adverse event already manifested in the
85% of cases in the first 2 weeks of treatment or at the
increase of the dose [3].
Also selective inhibitors of the reuptake of serotonin
(SSRI) have been related to angle-closed glaucoma [4],
even if less frequently than tricyclic antidepressants. Their
agonists activity at noradrenergic receptors (when
present), together with passive mydriasis induced by the
increase of serotonin levels, could favour the closing of
the irido-corneal angle. Two cases of glaucoma have
recently been reported in patients treated with citalopram,
the most selective among SSRIs in the reuptake of serot-
onin [5,6].
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We describe here the case of a patient in treatment with
citalopram that developed myopia and acute glaucoma 7
days after the beginning of the therapy with topiramate.
Case presentation
A 34 year-old man with diagnosis of migraine with and
without aura, particularly worsened both for duration and
for intensity in the last 3 years, was under treatment at our
Headache Centre of the University Hospital of Modena.
We prescribed topiramate 25 mg/day as treatment of
prophylaxis. According to the prescription, the patient
would have had to increase the dosing of the drug of 25
mg/day every 15 days, up to the dose of 100 mg/day, and
then to return then to our centre for a checkup.
The patient had also been taking citalopram 20 mg (1 tab-
let/day) for two months for the treatment of an anxious-
depressive syndrome. Neurological examination resulted
in the normality, with symmetrical deep tendon reflexes,
uninjured sensibility, absent nystagmus, and well per-
formed vestibulo-ocular reflexes. The fundus oculi was in
the limits for age, with preserved visual field. A magnetic
resonance imaging (MRI), performed one month before
to exclude possible organic causes of the worsening of
headache, didn't detect any pathological alteration.
Seven days after the start of the treatment with topiramate,
the patient complained of blurred vision and ocular pain
as an intense compression. The trouble persisted during
the evening, until the following morning, of unchanged
intensity. For these symptoms, the patient applied to a
nearby oculistic clinic, where a pressure of 40 mmHg in
both eyes was found, compatible with diagnosis of acute
glaucoma. The patient also presented a reduction of depth
of the anterior chamber, hyperaemia of the sclera and
light corneal edema. The fundus oculi showed however a
rosy, not excoriated pupilla, with clean borders. The
opthalmologist confirmed a severe acute myopia (right
eye = -5,5 diopters, left eye = -5 diopters).
The therapy with topiramate was immediately stopped
and the patient started the following antiglaucoma ther-
apy: acetazolamide 250 mg for twice a day in tablets,
latanoprost, timolol 0,50% 1 drop 3 times/day and pilo-
carpine 2% 1 drop for 3 times/day in eyewash. The same
day, a blood sample was taken for the determination of
topiramate levels by means of Fluorescence Polarized
Immuno Assay (FPIA). The plasma concentration was 1,7
μg/ml, therefore below the therapeutic range (2–25 μg/
ml).
Already 2 days later, ocular pressure was reduced to 14
mmHg in the right eye and to 17 mmHg in the left eye at
the ophthalmological checkup. After 4 days, the depth of
the anterior ocular chamber returned to normal and ocu-
lar tone subsequently reduced to 10 mmHgs in both eyes,
while an important loss of the visus remained (right eye =
-10,0 diopters, left eye = -6,5 diopters). The complete res-
olution of the symptomatology was atteined after 8 days
of antiglaucoma therapy and from the suspension of
topiramate: the patient eventually had a visus equal to 10/
10 bilaterally, and fundus oculi and ocular pressure
within the normal limits.
Discussion
The first clinical symptoms of glaucoma (blurred vision
and ocular pain) seem to be caused by an uveal effusion
and by an anterior rotation of the ciliary body. The conse-
quent ocular configuration would shallow the anterior
chamber and would close the irido-corneal angle, eventu-
ally precipitating the glaucomatous crisis [7].
The molecular mechanism of this serious side effect is not
clear yet, but the most shared hypothesis currently
remains the idiosyncratic reaction. It seems indeed diffi-
cult to relate the mechanisms of action of topiramate (spe-
cifically within the central nervous system) to the increase
of ocular pressure and the onset of angle closed glaucoma.
Furthermore, it is reported that topiramate modulates
voltage-dependent Na+ channels, thus reducing the firing
of cerebellar granule cells, and it seems contemporarily to
strengthen the activity of GABA (increasing post-synaptic
currents of GABAA receptors); finally, it would reduce the
effects of the activation of glutamatergic of AMPA-kainate
[8] subtype.
Topiramate is also a weak inhibitor of carbonic anhydrase
(particularly of subtypes II and IV), like other sulphona-
mides, and acetazolamide, a drug of the same class and
specific inhibitor of carbonic anhydrase, is paradoxically
an effective antiglaucoma drug, also used by our patient
for its activity of reduction of aqueous humor production.
In particular, it is hypothesized that the antiglaucomatous
activity of the sulphonamides depends on the inhibition
of the isoenzyme 12 (hCA XII) of the carbonic anhydrase.
Topiramate presents good affinity for this isoenzyme (KIs
of 3.8 NM), while it does not show significant selectiv-
ity[9]: this observation would confirm a possible antiglau-
coma mechanism of topiramate under normal
conditions. Furthermore, an overexpression of the gene
that codifies for this isoenzyme (hCA XII) of carbonic
anhydrase has been observed in glaucomatous patients
[10].
The ability to cause glaucoma seems therefore independ-
ent of the pharmacodynamic well-known effect of topira-
mate; the individual characteristics of the patient can
probably have had a decisive role.Cases Journal 2009, 2:87 http://www.casesjournal.com/content/2/1/87
Page 3 of 4
(page number not for citation purposes)
A peculiar element of this case is that our patient assumed
daily citalopram, a selective serotonin reuptake inhibitor,
as antidepressive therapy. Indeed, this drug is also impli-
cated in the development of angle-closed glaucoma [11].
Serotoninergic receptors have been identified in the ciliary
body in both animals and humans [12], suggesting that
serotonin has an important role of modulation of ocular
pressure. In experimental models, it has been observed
that serotonin, binding to serotoninergic intraocular
receptors 5-HT2 and 5-HT3, facilitates the contraction of
bovine ciliary muscle, with diminution of ocular pressure
[13]; but topical application of serotonin increases
intraocular pressure in dose-dependent manner in the
rabbit [14]. The overall effect of an increase of serotonin
on intraocular pressure is not completely clarified yet. A
case of acute glaucoma has been reported in a patient after
an overdose of citalopram, similarly to that observed with
fluoxetine [15].
On the basis of experimental and clinical data, we can
hypothesize that the mechanism of action of citalopram
contributes to the increasing of intraocular pressure in
dose-dependent manner. Remarkable clinical conse-
quences have not however been reported, because of
changes in plasmatic levels of citalopram, caused by con-
comitant assumption of other drugs [16]. It is therefore
unlikely that glaucoma was caused in our patient by an
increase of plasmatic concentrations of citalopram,
caused by topiramate-related inhibition of its elimina-
tion.
Topiramate is poorly metabolized by liver and it is a weak
inducer, not a pharmaco-metabolic inhibitor. The only
meaningful pharmacodynamic interaction from the clini-
cal point of view seems to be the reduction of plasmatic
concentration of estrogens in oral contraceptives, with
reduction of their efficacy [17]. About 85% of unmetabo-
lized topiramate is finally eliminated by urine; more than
16 hours after the start of symptomatology, plasmatic lev-
els of topiramate were even lower than therapeutic range,
excluding a possible dose-dependent adverse reaction to
this drug.
Conclusion
In conclusion, topiramate and citalopram were connected
both with the increasing of intraocular pressure and the
development of glaucoma. So far, no evidences have
emerged showing that a contemporary assumption of
both these drugs within therapeutic doses can increase the
risk of acute glaucoma, but it has been hypothesized that
selective serotonin reuptake inhibitors are able to
strengthen the uveal effusion of topiramate [18].
We cannot exclude that citalopram increases ocular pres-
sure in dose-dependent manner, through intraocular
accumulation of serotonin, consequently increasing the
risk of topiramate-induced glaucoma in a patient with a
predisposed genetic substratum.
We therefore recommend to pay particular attention to
the prescription of topiramate in patients in therapy with
citalopram or other antidepressants with similar mecha-
nisms of action.
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